Find a Clinical Trial

ORCHID

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID)

18-75

Learn more

SBT777101-01

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

18-70

Learn more

Organogenesis Knee OA

A Phase 3 Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients with Osteoarthritis of the Knee

18+

Learn more

RA-PROPR

A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients with Rheumatoid Arthritis

18+

Learn more

BIPI

A Study in People with Systemic Sclerosis to Test whether BI 685509 has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

18+

Learn more

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

18+

Learn more

Breast Cancer Database

Breast Cancer Database

18+

Learn more

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/​or Metastatic Breast Cancer

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)

16+

Learn more

Tai Chi and Microbiota in Osteoarthritis Study

Gut Microbiota and Osteoarthritis Study

55+

Learn more

HER2 Negative Breast Cancer

HCRN-BRE20-468 - A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

18+

Learn more